H. Lundbeck A/S (OTCMKTS:HLUYY) Short Interest Update

H. Lundbeck A/S (OTCMKTS:HLUYYGet Rating) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totalling 8,300 shares, a growth of 232.0% from the April 30th total of 2,500 shares. Based on an average trading volume of 1,900 shares, the short-interest ratio is currently 4.4 days.

Shares of HLUYY traded up $0.21 during trading hours on Thursday, reaching $23.36. 529 shares of the company traded hands, compared to its average volume of 1,183. The stock has a market capitalization of $4.65 billion, a P/E ratio of 14.24 and a beta of 0.60. The company has a quick ratio of 0.66, a current ratio of 0.98 and a debt-to-equity ratio of 0.26. H. Lundbeck A/S has a 12-month low of $21.06 and a 12-month high of $32.62. The business has a fifty day moving average price of $23.47 and a 200-day moving average price of $24.37.

The business also recently disclosed a dividend, which was paid on Tuesday, April 5th. Stockholders of record on Friday, March 25th were issued a dividend of $0.2044 per share. This represents a dividend yield of 0.85%. The ex-dividend date of this dividend was Thursday, March 24th. H. Lundbeck A/S’s dividend payout ratio (DPR) is presently 12.20%.

Several research firms have recently weighed in on HLUYY. Barclays decreased their price target on shares of H. Lundbeck A/S from 200.00 to 190.00 in a research note on Tuesday, February 22nd. Zacks Investment Research raised shares of H. Lundbeck A/S from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a research note on Monday, April 25th. Finally, Credit Suisse Group reduced their price objective on shares of H. Lundbeck A/S from 175.00 to 163.00 in a research note on Thursday, February 10th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $122.13.

H. Lundbeck A/S Company Profile (Get Rating)

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.

See Also

Receive News & Ratings for H. Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.